Medidata Solutions, Inc. (NASDAQ:MDSO) was upgraded by analysts at Dougherty & Co from a “neutral” rating to a “buy” rating in a report issued on Monday. The brokerage presently has a $75.00 price objective on the stock. Dougherty & Co’s target price points to a potential upside of 12.65% from the stock’s previous close.
A number of other analysts have also recently weighed in on MDSO. Zacks Investment Research raised shares of Medidata Solutions from a “sell” rating to a “hold” rating in a research report on Friday, November 10th. Jefferies Group LLC reiterated a “hold” rating and issued a $78.00 price objective on shares of Medidata Solutions in a report on Tuesday, August 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price objective (up previously from $75.00) on shares of Medidata Solutions in a report on Friday, July 21st. Royal Bank Of Canada assumed coverage on shares of Medidata Solutions in a report on Tuesday, September 19th. They issued a “sector perform” rating and a $82.00 price objective on the stock. Finally, BidaskClub lowered shares of Medidata Solutions from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Five equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $83.54.
Shares of Medidata Solutions (MDSO) opened at $66.58 on Monday. The company has a current ratio of 1.29, a quick ratio of 3.37 and a debt-to-equity ratio of 0.61. Medidata Solutions has a 12-month low of $47.77 and a 12-month high of $85.92. The firm has a market cap of $3,840.30, a price-to-earnings ratio of 79.14, a P/E/G ratio of 3.95 and a beta of 1.78.
Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings results on Thursday, October 26th. The company reported $0.33 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.02. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. The firm had revenue of $140.08 million during the quarter, compared to analysts’ expectations of $141.27 million. During the same period in the prior year, the company earned $0.28 EPS. The firm’s revenue was up 16.7% on a year-over-year basis. analysts anticipate that Medidata Solutions will post 0.77 earnings per share for the current year.
In related news, CEO Tarek Sherif sold 200,000 shares of the business’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $68.76, for a total transaction of $13,752,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert Taylor sold 5,000 shares of the business’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $71.39, for a total transaction of $356,950.00. Following the sale, the director now directly owns 49,372 shares of the company’s stock, valued at approximately $3,524,667.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 215,000 shares of company stock valued at $14,817,750. Insiders own 5.80% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Fortaleza Asset Management Inc. bought a new position in Medidata Solutions in the 3rd quarter worth about $155,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Medidata Solutions by 10.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,186 shares of the company’s stock worth $171,000 after purchasing an additional 208 shares during the last quarter. Polen Capital Management LLC bought a new position in Medidata Solutions in the 3rd quarter worth about $205,000. Parametrica Management Ltd bought a new position in Medidata Solutions in the 2nd quarter worth about $216,000. Finally, Cubist Systematic Strategies LLC bought a new position in Medidata Solutions in the 2nd quarter worth about $227,000. 97.52% of the stock is owned by institutional investors and hedge funds.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.